PMID: 701847Oct 1, 1978Paper

The epidermolytic toxin of Staphylococcus aureus: its failure to bind to cells and its detection in blister fluids of patients with bullous impetigo

The Journal of Investigative Dermatology
D H BakerK D Wuepper

Abstract

Radioiodinated staphylococcal epidermolytic toxin was found not to bind to erythrocytes, blood leukocytes, trypsin-dispersed keratinocytes, epidermis or whole skin. Moreover the toxin could not be found to bind to murine epithelia by indirect immunofluorescence methods. However, the toxin, measured by radioimmunoassay, could be eluted from the skin of mice undergoing epidermolysis following intraperitoneal injection of toxinogenic Staphylococcus aureus. Furthermore, epidemolysin was measured in the blister fluid of 3 of 5 children with bullous impetigo but not in blister fluid from control patients with other blistering eruptions. Thus epidermolysin has been demonstrated to be present in lesions of the staphylococcal epidermolytic toxin syndrome but its mechanism of action does not involve binding to cells.

Citations

Jan 6, 1986·FEBS Letters·T P Smith, C J Bailey
Feb 1, 1981·The Journal of Dermatology·K NishiokaS Sano
Mar 1, 1987·The Histochemical Journal·T P SmithC J Bailey
Sep 1, 1984·Clinical and Experimental Dermatology·G Guillet, D Fizet
Jan 1, 1980·The British Journal of Dermatology·C J Skerrow
Sep 1, 1990·The Journal of Dermatology·E GentilhommeJ Thivolet
Jul 24, 1980·Biochimica Et Biophysica Acta·C J BaileyJ P Arbuthnott
Sep 1, 1979·Microbiological Reviews·M Rogolsky
Mar 1, 1987·The Journal of Investigative Dermatology·J J LeydenG F Webster

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

© 2021 Meta ULC. All rights reserved